Parsippany Chapter Upcoming Events Join PCCI

 

Envisage-Wistar Partnership and Immunacel LLC

An early stage healthcare venture creation and management firm

Presenter: Vic Subbu, COO of Immunacel & Managing Partner of Envisage and Heather Steinman, VP of Business Development & Executive Director Tech Transfer Wistar Institute

 

Monday, June 8, 2015

Embassy Suites, Chesterbrook, Pennsylvania (directions)

 

About

 

Much has been said lately about how to improve the tech transfer situation. Wistar is meeting this challenge. Immunacel is the first of a series of developmental challenges and the Envisage-Wistar partnership solution becomes the meat of the evening's discussion.

 

Envisage LLC is an early stage healthcare venture creation and management firm. By focusing on key healthcare segments, Envisage aims to identify and advance promising healthcare innovations into value-add ventures.

 

IMMUNACCEL LLC is a Wistar Institute spin-out focused on accelerating the development of immune-mediated treatments for cancer and other unmet medical needs:

 

"We are launching as a service-based business targeting immunotherapy companies. We will be providing services to functionally validate existing pipeline candidates, identify new therapeutic candidates that can drive or inhibit activity of T-lymphocytes, and discover useful companion diagnostics to steer clinical development of said candidates. We operate with capital efficiency and leverage the existing Wistar infrastructure in driving value-add services."

 

Cancer immunotherapy has gained prominence over the last few years and as a result the industry has witnessed a rise in the number of pipeline candidates. The cancer immunotherapy market is projected to reach $35 billion by 2020 (Citigroup Report).

 

Life sciences companies are often faced with the challenge of finding the right model systems (in vitro and in vivo) to evaluate the mechanism and functionality of their drug candidates. In addition, given the changing oncology landscape, it is becoming increasingly important to efficiently, inexpensively and accurately identify the most promising therapeutic combinations. For young companies, the timeframe and expense required to set up innovative and reliable model systems in house can be exceedingly cost prohibitive.

 

IMMUNACCEL’s 3-D cancer-immune cell organotypic culture system is a physiologically relevant culture system utilizing primary human cancer cells and cytotoxic T cells (CTL) generated from patient T-cells, amongst fibroblasts and collagen assembled in a 3-D organotypic model. Their system was originally designed to understand the biology of tumor infiltrating lymphocytes (TILs) in the evaluation of biological therapeutics and small molecule inhibitors of chemokines and their receptors. Now, they are leveraging the power of the platform to exploit new targets on the immune-tumor interface and target the tumor microenvironment.

 

 

3 Major Issues

 

  1. Is this model/relationship unique?
  2. Will this relationship address the Life Sciences Industry's need for more focus?
  3. Will this benefit the Philadelphia region?

 

Program:

 

6:30 - Cocktails & Dinner (Cash bar and special 2-entree buffet menu)

8:00 - Vic Subbu, COO of Immunacel & Managing Partner of Envisage and Heather Steinman, VP of Business Development & Executive Director Tech Transfer Wistar Institute, will deliver the Company's "Elevator" Pitch to the Group

8:20 - Panel will address three major issues crucial to helping the Company reach the next level.

9:00 - Open discussion: members and guests

 

 

Available Media

Please note: All information obtained here is the property of those presenting and should not be copied or duplicated without written consent.

 

Slides

None available at this time

Audio

None available at this time

Video

None available at this time

Webcast

Envisage-Wistar Partnership and Immunacel Webcast - 06/08/15

00:00  Vik Subbu begins presentation
24:55  Panelists Presentations
49:28  Audience discussion

Contact Info:

 

 

Our Sponsors

EisnerAmperIdeas x Innovation Network i2nNew Jersey Institute of TechnologyScience Center

 

<Top of the page>

 

 

 

 

Questions or Coments?

Contact: Peter van der Kam,

peter@rxpcci.com | (610) 296-8086

 

 

 

Good Company! Good Drink! Good Food! Good Program! Good Fun!

 

Site Navigation

HOME  |  ABOUT PCCI  |   MAP / DIRECTIONS  |   JOIN US  |   BOARD MEMBERS  |   AFFILIATES  |  NEXT MEETING  |  ARCHIVES  |  PROFILES

CALENDAR OF EVENTS  |  PARSIPPANY CHAPTER  |  FEEDBACK / COMMENTS  |   CONTACT US

Pharmaceutical Consulting Consortium International, Inc.,

info@rxpcci.com or (610) 296-8086

Meetings Held at Embassy Suites - Valley Forge

888 Chesterbrook Blvd, Chesterbrook, Pennsylvania 19087

All content on this website is copyrighted and should not be reproduced without the consent of PCCI.

© Copyright 2016-2017

 

 

Tat Communication Inc